Trial Profile
A Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With Immune Thrombocytopenia (ITP) of ≤6 Months Duration
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 30 Mar 2022
Price :
$35
*
At a glance
- Drugs Avatrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Sponsors Dova Pharmaceuticals
- 15 Oct 2021 Status changed from not yet recruiting to withdrawn prior to enrolment as per corporate decision .
- 22 Sep 2021 New trial record